| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 75 | 2024 | 5592 | 6.760 |
Why?
|
| Uveal Neoplasms | 16 | 2024 | 189 | 6.260 |
Why?
|
| Skin Neoplasms | 32 | 2024 | 4889 | 2.470 |
Why?
|
| Ipilimumab | 14 | 2023 | 759 | 1.880 |
Why?
|
| Proto-Oncogene Proteins B-raf | 15 | 2022 | 1331 | 1.280 |
Why?
|
| GTP-Binding Protein alpha Subunits | 4 | 2024 | 41 | 1.190 |
Why?
|
| Interleukin-2 | 6 | 2021 | 891 | 1.060 |
Why?
|
| Antineoplastic Agents, Immunological | 8 | 2023 | 1335 | 1.050 |
Why?
|
| Choroid Neoplasms | 2 | 2014 | 45 | 0.840 |
Why?
|
| Vaccines, Subunit | 2 | 2021 | 127 | 0.830 |
Why?
|
| Benzimidazoles | 4 | 2020 | 442 | 0.820 |
Why?
|
| Neoadjuvant Therapy | 5 | 2023 | 5213 | 0.820 |
Why?
|
| Immunotherapy | 12 | 2023 | 3546 | 0.730 |
Why?
|
| Toll-Like Receptors | 1 | 2021 | 170 | 0.720 |
Why?
|
| Neoplasm Metastasis | 14 | 2022 | 5330 | 0.700 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2022 | 384 | 0.670 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2020 | 356 | 0.630 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2023 | 16610 | 0.630 |
Why?
|
| Dacarbazine | 4 | 2017 | 505 | 0.610 |
Why?
|
| Antineoplastic Agents | 10 | 2021 | 14653 | 0.610 |
Why?
|
| Mucous Membrane | 3 | 2023 | 264 | 0.540 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 6 | 2022 | 1015 | 0.500 |
Why?
|
| Programmed Cell Death 1 Receptor | 7 | 2021 | 1091 | 0.500 |
Why?
|
| Humans | 86 | 2024 | 271941 | 0.490 |
Why?
|
| Biomarkers, Tumor | 7 | 2020 | 10750 | 0.480 |
Why?
|
| Heart Neoplasms | 2 | 2014 | 216 | 0.470 |
Why?
|
| Scalp | 1 | 2016 | 155 | 0.470 |
Why?
|
| Liver Neoplasms | 5 | 2021 | 4811 | 0.460 |
Why?
|
| Meningeal Neoplasms | 1 | 2018 | 473 | 0.450 |
Why?
|
| CTLA-4 Antigen | 5 | 2023 | 681 | 0.430 |
Why?
|
| Middle Aged | 42 | 2024 | 90427 | 0.410 |
Why?
|
| Patient Care Team | 1 | 2018 | 830 | 0.410 |
Why?
|
| Male | 51 | 2024 | 128995 | 0.400 |
Why?
|
| Molecular Targeted Therapy | 6 | 2022 | 2400 | 0.400 |
Why?
|
| Female | 48 | 2024 | 149187 | 0.350 |
Why?
|
| Neoplasms | 13 | 2023 | 15928 | 0.340 |
Why?
|
| Aged | 34 | 2024 | 73494 | 0.330 |
Why?
|
| Adult | 34 | 2021 | 81889 | 0.330 |
Why?
|
| Pyridones | 4 | 2019 | 362 | 0.320 |
Why?
|
| Quality of Life | 1 | 2023 | 4749 | 0.310 |
Why?
|
| Neoplasms, Second Primary | 4 | 2022 | 1388 | 0.310 |
Why?
|
| Clinical Trials as Topic | 7 | 2020 | 3853 | 0.300 |
Why?
|
| Mutation | 13 | 2024 | 15941 | 0.280 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 31060 | 0.270 |
Why?
|
| Quinazolines | 1 | 2011 | 953 | 0.270 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 3393 | 0.270 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2020 | 2417 | 0.260 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2022 | 4964 | 0.260 |
Why?
|
| Prognosis | 14 | 2021 | 22550 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2023 | 3980 | 0.260 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2016 | 51 | 0.250 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2020 | 640 | 0.250 |
Why?
|
| Neoplasm Staging | 14 | 2023 | 13993 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 3 | 2022 | 4496 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 10365 | 0.230 |
Why?
|
| Injections, Intralesional | 2 | 2021 | 166 | 0.220 |
Why?
|
| Carbamates | 2 | 2020 | 81 | 0.220 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2023 | 68 | 0.220 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2023 | 629 | 0.210 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 4138 | 0.210 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2024 | 224 | 0.210 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2022 | 1841 | 0.210 |
Why?
|
| Treatment Outcome | 14 | 2023 | 33874 | 0.210 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2021 | 968 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 2 | 2023 | 692 | 0.200 |
Why?
|
| Sulfonamides | 3 | 2020 | 1919 | 0.200 |
Why?
|
| Oximes | 3 | 2018 | 192 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2024 | 2357 | 0.200 |
Why?
|
| B7-H1 Antigen | 5 | 2023 | 1075 | 0.200 |
Why?
|
| Melanoma, Experimental | 2 | 2021 | 385 | 0.200 |
Why?
|
| Cancer Vaccines | 2 | 2021 | 754 | 0.200 |
Why?
|
| T-Lymphocytes | 5 | 2021 | 3947 | 0.200 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2022 | 109 | 0.190 |
Why?
|
| Pyrimidinones | 3 | 2018 | 317 | 0.190 |
Why?
|
| Dietary Fiber | 1 | 2021 | 126 | 0.190 |
Why?
|
| DNA Mutational Analysis | 3 | 2016 | 2365 | 0.190 |
Why?
|
| Arthritis | 1 | 2022 | 148 | 0.190 |
Why?
|
| Urethral Neoplasms | 1 | 2021 | 64 | 0.190 |
Why?
|
| Disease Progression | 6 | 2023 | 6910 | 0.180 |
Why?
|
| Young Adult | 13 | 2021 | 22127 | 0.180 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2020 | 16 | 0.180 |
Why?
|
| Medical Oncology | 2 | 2020 | 1463 | 0.180 |
Why?
|
| Hypoparathyroidism | 1 | 2020 | 49 | 0.180 |
Why?
|
| Combined Modality Therapy | 8 | 2023 | 9044 | 0.170 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 311 | 0.170 |
Why?
|
| Hypocalcemia | 1 | 2020 | 59 | 0.170 |
Why?
|
| Kidney Neoplasms | 3 | 2019 | 3153 | 0.170 |
Why?
|
| Vaginal Neoplasms | 1 | 2021 | 155 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2018 | 5421 | 0.170 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2020 | 36 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 433 | 0.170 |
Why?
|
| Drug Carriers | 1 | 2021 | 336 | 0.170 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 207 | 0.160 |
Why?
|
| Probiotics | 1 | 2021 | 240 | 0.160 |
Why?
|
| Congresses as Topic | 1 | 2020 | 296 | 0.160 |
Why?
|
| Uvea | 1 | 2018 | 4 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2021 | 366 | 0.160 |
Why?
|
| Enterocolitis | 1 | 2018 | 48 | 0.150 |
Why?
|
| Recombinant Proteins | 2 | 2021 | 3072 | 0.150 |
Why?
|
| Infliximab | 1 | 2018 | 140 | 0.150 |
Why?
|
| Hepatitis C, Chronic | 1 | 2023 | 469 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 12012 | 0.150 |
Why?
|
| Hepatitis C | 1 | 2023 | 551 | 0.150 |
Why?
|
| Sarcoma, Myeloid | 1 | 2018 | 94 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2021 | 360 | 0.150 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 118 | 0.150 |
Why?
|
| Imidazoles | 3 | 2018 | 1056 | 0.140 |
Why?
|
| Nevus, Pigmented | 1 | 2017 | 116 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 2679 | 0.140 |
Why?
|
| Eukaryotic Initiation Factor-1 | 1 | 2016 | 15 | 0.140 |
Why?
|
| Autoantibodies | 1 | 2020 | 600 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 909 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinases | 2 | 2019 | 188 | 0.140 |
Why?
|
| Biological Products | 1 | 2020 | 316 | 0.140 |
Why?
|
| Disease-Free Survival | 7 | 2020 | 10259 | 0.140 |
Why?
|
| Brain Neoplasms | 3 | 2019 | 4993 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 664 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2018 | 292 | 0.130 |
Why?
|
| Colitis | 1 | 2019 | 344 | 0.130 |
Why?
|
| RNA Splicing Factors | 1 | 2016 | 154 | 0.130 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2015 | 33 | 0.130 |
Why?
|
| Ophthalmology | 1 | 2018 | 203 | 0.130 |
Why?
|
| Carboplatin | 1 | 2018 | 879 | 0.120 |
Why?
|
| Risk Factors | 5 | 2021 | 18047 | 0.120 |
Why?
|
| Peptides | 1 | 2021 | 1529 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 566 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2019 | 669 | 0.120 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1113 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 550 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2016 | 682 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2016 | 255 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2018 | 1432 | 0.120 |
Why?
|
| Risk Assessment | 4 | 2022 | 6883 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2020 | 1349 | 0.120 |
Why?
|
| Computational Biology | 1 | 2020 | 1282 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2014 | 490 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 1429 | 0.110 |
Why?
|
| Research | 1 | 2016 | 431 | 0.110 |
Why?
|
| Lymphatic Metastasis | 3 | 2020 | 4968 | 0.110 |
Why?
|
| Leuprolide | 1 | 2013 | 67 | 0.110 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2012 | 48 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2021 | 2119 | 0.100 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 138 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 889 | 0.100 |
Why?
|
| Intracranial Hemorrhages | 1 | 2012 | 120 | 0.100 |
Why?
|
| Paclitaxel | 1 | 2018 | 2099 | 0.090 |
Why?
|
| Aftercare | 1 | 2013 | 255 | 0.090 |
Why?
|
| Survival Analysis | 6 | 2022 | 9325 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 1340 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2016 | 609 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 1659 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2016 | 1230 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 503 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 4352 | 0.090 |
Why?
|
| Incidence | 4 | 2021 | 5861 | 0.080 |
Why?
|
| Mass Screening | 1 | 2018 | 1547 | 0.080 |
Why?
|
| Cohort Studies | 5 | 2021 | 9494 | 0.080 |
Why?
|
| Survival Rate | 5 | 2022 | 12533 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2020 | 3080 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 2034 | 0.080 |
Why?
|
| Biomarkers | 2 | 2019 | 5114 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 2174 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 1054 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2021 | 758 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2429 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2016 | 1699 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2012 | 1020 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2011 | 1620 | 0.070 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 376 | 0.070 |
Why?
|
| Clone Cells | 2 | 2020 | 589 | 0.070 |
Why?
|
| Lymphopenia | 1 | 2009 | 211 | 0.070 |
Why?
|
| Animals | 6 | 2022 | 62823 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 1059 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2012 | 792 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2022 | 2366 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2011 | 847 | 0.070 |
Why?
|
| Antiviral Agents | 2 | 2023 | 1255 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 7237 | 0.070 |
Why?
|
| Time Factors | 3 | 2021 | 13130 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 6270 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 1409 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 2 | 2019 | 1323 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 3704 | 0.060 |
Why?
|
| Biopsy | 3 | 2017 | 3544 | 0.060 |
Why?
|
| Texas | 2 | 2018 | 6435 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 1966 | 0.060 |
Why?
|
| Darier Disease | 1 | 2024 | 8 | 0.060 |
Why?
|
| Eyebrows | 1 | 2024 | 18 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 15269 | 0.060 |
Why?
|
| New York | 1 | 2023 | 104 | 0.060 |
Why?
|
| Sustained Virologic Response | 1 | 2023 | 62 | 0.050 |
Why?
|
| Nausea | 2 | 2019 | 540 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2023 | 1136 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2011 | 2383 | 0.050 |
Why?
|
| Adolescent | 6 | 2021 | 32687 | 0.050 |
Why?
|
| Viremia | 1 | 2023 | 182 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5755 | 0.050 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2024 | 199 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2021 | 1483 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 52 | 0.050 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2024 | 294 | 0.050 |
Why?
|
| Rats, Inbred BUF | 1 | 2021 | 26 | 0.050 |
Why?
|
| MART-1 Antigen | 1 | 2021 | 113 | 0.050 |
Why?
|
| Drug Compounding | 1 | 2021 | 73 | 0.050 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2021 | 161 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 164 | 0.050 |
Why?
|
| Cisplatin | 2 | 2021 | 2497 | 0.050 |
Why?
|
| Hydrolases | 1 | 2021 | 132 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3026 | 0.040 |
Why?
|
| Mice | 4 | 2022 | 36054 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2023 | 423 | 0.040 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2020 | 40 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 14881 | 0.040 |
Why?
|
| Hydrogels | 1 | 2021 | 131 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 298 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2021 | 316 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 2020 | 115 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 240 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2023 | 39800 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 773 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 261 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 382 | 0.040 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2020 | 181 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2020 | 13402 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2021 | 1860 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 4891 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 272 | 0.040 |
Why?
|
| Dermoscopy | 1 | 2017 | 15 | 0.040 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 232 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 319 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2016 | 12223 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 2024 | 1015 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 865 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 380 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 337 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 726 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2021 | 2975 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2021 | 642 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2018 | 102 | 0.040 |
Why?
|
| Ribosomal Protein S6 | 1 | 2016 | 48 | 0.030 |
Why?
|
| Melanocytes | 1 | 2017 | 241 | 0.030 |
Why?
|
| Cell-Free System | 1 | 2016 | 175 | 0.030 |
Why?
|
| Remission Induction | 2 | 2013 | 3645 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2024 | 1904 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2022 | 1048 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1377 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2016 | 173 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2018 | 404 | 0.030 |
Why?
|
| Standard of Care | 1 | 2018 | 276 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 5195 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 278 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 550 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2015 | 117 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 2270 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 298 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 229 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 7827 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2015 | 275 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 317 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 125 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2351 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 690 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2017 | 829 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 1074 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3540 | 0.030 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2013 | 94 | 0.030 |
Why?
|
| Point Mutation | 1 | 2016 | 793 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2015 | 835 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 690 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 595 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 908 | 0.030 |
Why?
|
| Interleukin-7 | 1 | 2013 | 93 | 0.030 |
Why?
|
| Taxoids | 1 | 2016 | 1010 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2013 | 186 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 341 | 0.030 |
Why?
|
| Skin | 1 | 2017 | 1284 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 2439 | 0.030 |
Why?
|
| Rats | 1 | 2021 | 6640 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 485 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1212 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2018 | 2866 | 0.020 |
Why?
|
| Genomics | 1 | 2022 | 2830 | 0.020 |
Why?
|
| Transcriptome | 1 | 2020 | 1950 | 0.020 |
Why?
|
| Recurrence | 1 | 2019 | 4887 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2018 | 1451 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2016 | 1197 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 2054 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 5118 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 1555 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2024 | 5506 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2014 | 1146 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2014 | 964 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 4071 | 0.020 |
Why?
|
| Telomere | 1 | 2012 | 546 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 1950 | 0.020 |
Why?
|
| Phenotype | 1 | 2020 | 6516 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 4984 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 848 | 0.020 |
Why?
|
| Vomiting | 1 | 2009 | 361 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 2048 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 1972 | 0.020 |
Why?
|
| Disease Management | 1 | 2013 | 1111 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 2035 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 1590 | 0.020 |
Why?
|
| Cytokines | 1 | 2015 | 2841 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 5105 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6210 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2018 | 3148 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 1177 | 0.020 |
Why?
|
| Neutropenia | 1 | 2009 | 1001 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 5187 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2012 | 5788 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 872 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 9101 | 0.010 |
Why?
|
| United States | 1 | 2020 | 16053 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3363 | 0.010 |
Why?
|